Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lademirsen - Regulus Therapeutics

Drug Profile

Lademirsen - Regulus Therapeutics

Alternative Names: Lademirsen sodium; RG 012; RG 456070; SAR 339375

Latest Information Update: 21 Oct 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regulus Therapeutics; Sanofi
  • Developer Regulus Therapeutics
  • Class Antisense oligoribonucleotides; MicroRNAs; Urologics
  • Mechanism of Action MicroRNA inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hereditary nephritis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hereditary nephritis

Most Recent Events

  • 29 Sep 2020 Lademirsen is still in phase II trials for Hereditary nephritis in USA and United Kingdom (SC) (NCT02855268)
  • 13 Nov 2019 Sanofi plans to submit a regulatory application for Alport syndrome, in 2023 or later
  • 04 Nov 2019 Sanofi and Regulus Therapeutics reinitiate patient enrolment in the phase II HERA trial in Hereditary nephritis in USA and United Kingdom (SC) (NCT02855268)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top